Dallas, TX (PRWEB) February 1, 2006
Zyvex Corporation, a leading molecular nanotechnology company specializing in micro and nanomanufacturing, micro electro mechanical systems (MEMS), and nanomaterials has selected Diabetech, LP as its medical device development and commercialization partner for their wireless sensor implant targeting real-time blood glucose levels in the body.
Diabetech provides the know-how and patented technologies necessary to develop the innovative patient’s handheld device for not only displaying the glucose levels from the implant to the patient but also for automatically relaying that information in real-time to GlucoDYNAMIX™, Diabetech’s clinical management system. Diabetech will also be responsible for commercializing this leading-edge medical device technology as part of its Virtual-Loop™ Program.
The collaboration is called Project GeNI ™, which stands for Glucose Nanobiosensor Implant. Both firms are located in the Dallas-Fort Worth Metroplex of North Texas and have been working together for the past several months in the assessment & design phase of the project.
According to Jim Von Ehr, Zyvex Chairman & CEO, “This program leverages Zyvex's two related Federally-funded programs and Diabetech's award-winning remote patient monitoring technology to accelerate the development of a wireless, implantable device which enables continuous availability of glucose levels within the diabetic patient.”
Diabetes is a big problem and only getting bigger every day. Diabetes is the seventh leading cause of death in the United States and is a disease that affects more than 225 million people worldwide. For most people, treatment of diabetes is aimed at keeping blood glucose near normal levels at all times. That is accomplished today through a painful and imperfect process of isolated patients performing 4 to 12 finger-sticks per day, which also require expensive single-use disposable blood glucose test strips, frequent spot testing of the blood, insulin injections, carefully measured food intake, exercise and more. Assuming you can simplify the process, a patient-friendly CGM system represents a clear path to improving people’s lives and cost-savings in the billions of dollars.
“One of the most exciting aspects of this program and what makes it special is that all of the technological elements required to make the fourth generation of glucose monitoring a reality appear to be already available. The challenge will be integrating these technologies and testing them to make sure we have solved not only the physiological obstacles but also those which deal with the real world including a system accepted by health plans, physicians and patients” says Kevin McMahon, President & CEO of Diabetech.
Funding to carry out this research is being generated through program-specific grants and targeted investment. For more information including investor inquiries, please contact Kevin McMahon from Diabetech at 877.My.Gluco or send email to Diabetech.
# # #